A Phase 4 interventional study of Telmisartan and Losartan in Essential Hypertension and Metabolic Syndrome, sponsored by Chong Kun Dang Pharmaceutical. Not yet recruiting. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2023-05-06.
Sponsored by Chong Kun Dang Pharmaceutical · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Essential Hypertension by Chong Kun Dang Pharmaceutical — 2 open to participants now, 2 under way, 1 of them phase 3. Essential Hypertension · Chong Kun Dang Pharmaceutical.
Among the 18 studies in Essential Hypertension by Chong Kun Dang Pharmaceutical, this one is the 10th largest by planned enrollment of the 17 interventional ones that give a count, is one of 3 that started in 2023, is one of 2 in phase 4, and was the 15th registered.
480 studies on the registry are indexed under Essential Hypertension; 76 are open to participants now.
Browse Essential Hypertension studies →2 of the 18 studies in Essential Hypertension by Chong Kun Dang Pharmaceutical are open now, in 1 country. Recruiting first, the newest first:
Chong Kun Dang Pharmaceutical · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 116 is below the median of 144 across 407 interventional studies indexed under Essential Hypertension.
Median enrollment 169 across the 17 interventional studies, 20,000 across the 1 observational. Of the 12 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Chong Kun Dang Pharmaceutical is the lead sponsor of 299 studies on the registry; 14 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 18 studies in Essential Hypertension by Chong Kun Dang Pharmaceutical, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multi-center, randomized, open-label, active comparator-controlled, phase 4 clinical trial to evaluate the blood pressure control of Telmisartan or Losartan in essential hypertensive patients with metabolic syndrome
Participants were randomly assigned in a 1:1 ratio to the following group; the test group [Telmisartan 40 mg + S-Amlodopine 2.5 mg], the control group [Losartan 50 mg + S-Amlodopine 2.5 mg]. If the blood pressure measured at 6 weeks time (Visit 3) based on the random allocation date (Visit 2) is MSSBP ≥140 mmHg or MSDBP ≥90 mmHg, the test group will increase the Telmisartan 80 mg, the control group will increase the dose to 100 mg for 6 weeks from Visit 3 to Visit 4(End of study). However, if the need of dose increasing is not required according to the investigator's judgment, the current dose can be maintained. All clinical trial drugs are administered orally once a day, and it is recommended to be administered at the same time(am) for 12 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
[Screening/Run-in period (Visit 1)]
[Randomization (Visit 2)]
Patients whose average sitting systolic or diastolic blood pressure measured in the arm selected as the reference arm during the screening test at the time of randomization (Visit 2) corresponds to the following
Exclusion Criteria:
Patients whose blood pressure measured at the time of screening/introduction (Visit 1) corresponds to any of the following
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Telmitrend Tab.(Telmisartan) 40mg(80mg) + Anydipine-S(S-amlodipine) Tab. 2.5mg
Drug: Telmisartan
Cozaar Tab.(Losartan) 50mg(100mg) + Anydipine-S(S-amlodipine) Tab. 2.5mg
Drug: Losartan
Subjects assigned to the test group are oral administered Telmisartan 40 mg and S-Amlodopine 2.5 mg once a day for 12 weeks. However, if the blood pressure measured at 6 weeks after random allocation (Visit 3) is MSSBP ≥140 mmHg or MSDBP ≥ 90 mmHg, increase the dose to Telmisartan 80 mg for 6 weeks from Visit 3 to Visit 4 (End of study). However, if the need of dose increasing is not required according to the tester's judgment, the current dose can be maintained.
Subjects assigned to the control group are oral administered Losartan 50 mg and S-Amlodopine 2.5 mg once a day for 12 weeks. However, if the blood pressure measured at 6 weeks after random allocation (Visit 3) is MSSBP ≥140 mmHg or MSDBP ≥ 90 mmHg, increase the dose to Losartan 100 mg for 6 weeks from Visit 3 to Visit 4 (End of study). However, if the need of dose increasing is not required according to the tester's judgment, the current dose can be maintained.
MSSBP change
MSSBP change between administration groups after 12 weeks (Visit 4) compared to baseline (Visit 2)
Time frame: Baseline (Visit 2), 12 weeks (Visit 4)
MSSBP change
MSSBP change between administration groups after 6 weeks (Visit 3) compared to baseline (Visit 2)
Time frame: Baseline (Visit 2), 6 weeks (Visit 3)
MSDBP change
MSDBP change between administration groups compared to baseline (Visit 2) after 6 weeks (Visit 3) and 12 weeks (Visit 4)
Time frame: Baseline (Visit 2), 6 weeks (Visit 3), 12 weeks (Visit 4)
Blood pressure normalization ratio
Blood pressure normalization ratio (ratio of subjects with MSSBP \<140 mmHg and MSDBP \<90 mmHg) after 6 weeks (Visit 3) and 12 weeks (Visit 4) compared to baseline (Visit 2) between administration groups
Time frame: Baseline (Visit 2), 6 weeks (Visit 3), 12 weeks (Visit 4)
Blood pressure response rate
Blood pressure response rate (MSSBP reduction ≥20 mmHg and MSDBP reduction ≥10 mmHg) after 6 weeks (Visit 3) and 12 weeks (Visit 4) compared to baseline (Visit 2) between treatment groups
Time frame: Baseline (Visit 2), 6 weeks (Visit 3), 12 weeks (Visit 4)
Changes in HOMA-IR
Changes in HOMA-IR\[(Fasting insulin(mU/L)×Fasting glucose(nmol/L))/22.5\]
Time frame: Baseline (Visit 2), 6 weeks (Visit 3), 12 weeks (Visit 4)
Changes in HOMA-β
Changes in HOMA-β\[(20×Fasting insulin(mU/L))/(Fasting glucose(nmol/L)-3.5)\]
Time frame: Baseline (Visit 2), 6 weeks (Visit 3), 12 weeks (Visit 4)
Changes in Glucose
Changes in Glucose(nmol/L)
Time frame: Baseline (Visit 2), 6 weeks (Visit 3), 12 weeks (Visit 4)
Changes in Insulin
Changes in Insulin(mU/L) after 6 weeks (Visit 3) and 12 weeks (Visit 4) compared to baseline (Visit 2) between administration groups
Time frame: Baseline (Visit 2), 6 weeks (Visit 3), 12 weeks (Visit 4)
Changes in HbA1c
Changes in HbA1c (%) after 6 weeks (Visit 3) and 12 weeks (Visit 4) compared to baseline (Visit 2) between administration groups
Time frame: Baseline (Visit 2), 6 weeks (Visit 3), 12 weeks (Visit 4)
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jun 2023; primary completion for Dec 2023, 6 months later.
Of 22 phase 4 interventional studies under Essential Hypertension, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 36. This study's planned 6 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Telmisartan
Chong Kun Dang Pharmaceutical →